+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the efficacy and safety of enpatoran in adults aged 18 to 75 with active cutaneous manifestations of lupus erythematosus, either with or without systemic disease. This global, multicenter Phase 3 study aims to understand how enpatoran works compared to a placebo in addition to standard care over a 24-week treatment period. The study is sponsored by EMD Serono Research & Development Institute, Inc. and includes participants diagnosed with Discoid Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus, andor Acute Cutaneous Lupus Erythematosus, with or without systemic lupus erythematosus. Participants are randomly assigned to receive either enpatoran tablets or matching placebo tablets taken orally twice daily for 24 weeks while continuing their standard of care treatments. The study intervention is administered as film-coated tablets, and participants are monitored throughout the treatment period. Visits occur every four weeks, with a televisit at Week 2, allowing ongoing assessment of the participants condition and response to treatment. Throughout the study, participants undergo regular evaluations including the Cutaneous Lupus Erythematosus Disease Area and Severity Index CLASI and other measures of lupus activity and symptom changes. Researchers monitor for treatment-emergent adverse events, serious adverse events, and laboratory abnormalities from Day 1 to Week 24. The primary outcome is the percentage of participants achieving a 70% or greater reduction in CLASI-A score at Week 24. Total study participation can last up to 35 weeks, including screening and follow-up assessments.

Age: 18Years - 75YearsAll GendersPhase 3
70 locations
S

Actively Recruiting

Researchers are evaluating the safety, tolerability, pharmacodynamics, and efficacy of multiple ascending doses of the investigational drug CNP-103 in people aged 12 to 35 who have recently been diagnosed with Stage 3 Type 1 Diabetes within the last 6 months. This Phase 1b2a trial aims to understand how CNP-103 works and its effects in this population over about 393 days. Participants will receive three intravenous doses of CNP-103 at varying amounts 100 mg, 300 mg, or 600 mg on Days 1, 8, and 90. The study includes an initial Screening Period lasting 28 days, followed by a 90-day Treatment Period with dosing, and then a Post-Dose Evaluation phase lasting 275 days to monitor participants after treatment. Dosing for the Expansion Cohort will be based on results from the earlier Escalation Phase. During the study, participants will undergo assessments including safety and immune safety monitoring from Day 1 through Day 365. Researchers will collect data on how participants tolerate the treatment, any side effects, and immune responses. Participants will be monitored regularly throughout the nearly 13-month study period, including visits for drug administration, laboratory tests, and evaluations to measure the study outcomes and ensure safety.

Age: 12Years - 35YearsAll GendersPhase 1Phase 2
45 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
P

Actively Recruiting

Researchers are evaluating a new digital therapeutic aimed at preventing posttraumatic stress disorder PTSD and cannabis use disorder CUD in women who have recently experienced sexual assault. The study focuses on women presenting for emergency care after assault, as many develop chronic PTSD and face increased risk for CUD. This research also trains investigators in advanced clinical trial methods and biobehavioral mechanisms related to PTSD-CUD prevention. Participants will be randomly assigned to one of two behavioral intervention groups. One group will receive the RISE Guide, a brief cognitive behavioral program delivered via smartphone within three weeks post-assault, teaching stress education, cognitive retraining, and anxiety sensitivity reduction techniques supported by personalized ecological momentary intervention reminders. The other group will use the Breathe2Relax app, which provides diaphragm breathing exercises for stress management, along with reminders to engage with the relaxation exercises. During the study, participants will be monitored for anxiety sensitivity using the Anxiety Sensitivity Index-3 at 6 weeks, as well as various measures of cannabis use, anxiety, depression, and PTSD symptoms over 6 months. The study includes smartphone-based assessments, ecological momentary interventions, and questionnaires to track symptoms and intervention adherence. The total study duration extends to six months, including ongoing evaluation and support.

Age: 18Years +FEMALEPhase 1Phase 2
6 locations
T

Actively Recruiting

This research aims to evaluate the WeCan-Rural program, designed to help female breast cancer survivors in rural, medically underserved areas improve their health and reduce heart disease risk. The study focuses on survivors with stage I-III breast cancer who have completed treatment within the last five years and have a body mass index over 30. It will assess whether the program is acceptable, easy to follow, and helpful compared to standard care. Participants will be randomly assigned to either the WeCan-Rural program or receive standard health information from the National Cancer Institute. The WeCan-Rural program involves twelve weekly one-hour video sessions via Zoom led by a trained therapist, teaching skills for healthy eating, physical activity, symptom management, and building healthy habits. Participants will receive tools like a wireless activity tracker, scale, and blood pressure monitor and may be provided a tablet and data plan if needed. During the study, participants will visit their clinic twice about 12 weeks apart for weight, blood pressure, blood samples, and a walking test. They will complete online surveys about their health, diet, symptoms, physical activity, and confidence in managing their health. Researchers will measure satisfaction, acceptability, and changes in heart health indicators, weight, symptoms, diet, and physical activity. The study aims to follow participants for approximately 12 to 14 weeks after baseline.

Age: 18Years +FEMALEPhase Not Applicable
5 locations